SCHEMBL4126384

SCHEMBL4126384

CCc1c(O)cc(C)c(C(=O)O)c1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.56
MAPT P10636 2/20 0.56
APP P05067 3/20 0.54
BACE1 P56817 3/20 0.54
PTPN1 P18031 2/20 0.54
ACHE P22303 1/20 0.50
LDHA P00338 4/20 0.46
LDHB P07195 4/20 0.46
PLA2G2A P14555 1/20 0.41
USP2 O75604 1/20 0.41
HSD17B10 Q99714 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
PTPN11 Q06124 1/20 0.40
ALDH1A1 P00352 3/20 0.39
MAPK1 P28482 3/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10722732 0.87 LDHA (0.58) CYP3A4MAPTAPPBACE1PTPN1
SCHEMBL18204384 0.85 CYP3A4 (0.45) CYP3A4MAPTAPPBACE1PTPN1
SCHEMBL5680835 0.83 CYP3A4 (0.46) CYP3A4MAPTAPPBACE1PTPN1
SCHEMBL27890160 0.82 SLC6A3 (0.45) CYP3A4MAPTAPPBACE1PTPN1
SCHEMBL8674806 0.80 CYP3A4 (0.51) CYP3A4MAPTAPPBACE1PTPN1
SCHEMBL19193899 0.79 CYP3A4 (0.63) CYP3A4MAPTAPPBACE1PTPN1
SCHEMBL10764425 0.79 P2RX3 (0.50) CYP3A4MAPTAPPBACE1PTPN1
3-Methylorsellinic Acid SCHEMBL30016632 0.78 CYP3A4 (0.61) CYP3A4MAPTAPPBACE1PTPN1
3-Methylorsellinic Acid SCHEMBL31741224 0.78 CYP3A4 (0.61) CYP3A4MAPTAPPBACE1PTPN1
3-Methylorsellinic Acid SCHEMBL963740 0.78 CYP3A4 (0.61) CYP3A4MAPTAPPBACE1PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001999-A1 HYDROPHILIC OIL REPELLENT POLYMER SUMITOMO CHEMICAL CO (JP) 2026-01-01 US disclosed
EP-4578894-A1 HYDROPHILIC OIL REPELLENT POLYMER Sumitomo Chemical Company, Limited (JP) 2025-07-02 EP disclosed
EP-4578895-A1 POLYMER, RESIN COMPOSITION, MOLDED BODY, AND POLYMER PRODUCTION METHOD Sumitomo Chemical Company, Limited (JP) 2025-07-02 EP disclosed
WO-2024043326-A1 HYDROPHILIC OIL REPELLENT POLYMER 住友化学株式会社 2024-02-29 WO disclosed
WO-2024043327-A1 POLYMER, RESIN COMPOSITION, MOLDED BODY, AND POLYMER PRODUCTION METHOD 住友化学株式会社 2024-02-29 WO disclosed
US-20230129965-A1 HYDROPHILIC AND OLEOPHOBIC POLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-04-27 US disclosed
EP-4130057-A1 HYDROPHILIC OIL REPELLENT POLYMER Sumitomo Chemical Company, Limited (JP) 2023-02-08 EP disclosed
WO-2022255400-A1 CLEANER FOR INDOOR WATER USE SITES 住友化学株式会社 2022-12-08 WO disclosed
US-11459445-B2 Composition and molded body SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2022-10-04 US disclosed
CN-111684019-B Composition and molded article 住友化学株式会社 2022-08-02 CN disclosed
US-20210054169-A1 COMPOSITION AND MOLDED BODY SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2021-02-25 US disclosed
EP-3753986-A1 COMPOSITION AND MOLDED BODY SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2020-12-23 EP disclosed
CN-111684019-A Composition and molded article 住友化学株式会社 2020-09-18 CN disclosed
US-8481519-B2 Isolation of atraric acid, synthesis of atraric acid derivatives, and use of atraric acid and the derivatives thereof for the treatment of benign prostatic hyperplasia, prostate carcinoma and spinobulbar muscular atrophy LTS LOHMANN THERAPIE-SYSTEME AG (DE) 2013-07-09 US disclosed
EP-1850857-B1 ISOLATION OF ATRARIC ACID, SYNTHESIS OF ATRARIC ACID DERIVATIVES, AND USE OF ATRARIC ACID AND THE DERIVATIVES THEREOF FOR THE TREATMENT OF PROSTATE CARCINOMA. LOHMANN THERAPIE SYST LTS (DE) 2013-05-22 EP disclosed
US-20090143466-A1 Isolation of Atraric Acid, Synthesis of Atraric Acid Derivatives, and Use of Atraric Acid and the Derivatives Thereof for the Treatment of Benign Prostatic Hyperplasia, Prostate Carcinoma and Spinobulbar Muscular Atrophy LTS LOHMANN THERAPIE-SYSTEME AG (DE) 2009-06-04 US disclosed
US-4682193-A HEAT SENSITIVE, STORAGE STABILITY FUJI PHOTO FILM CO., LTD. (JP) 1987-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143466-A1 Isolation of Atraric Acid, Synthesis of Atraric Acid Derivatives, and Use of Atraric Acid and the Derivatives Thereof for the Treatment of Benign Prostatic Hyperplasia, Prostate Carcinoma and Spinobulbar Muscular Atrophy RARB, RARA, AR CYP3A4 3211/4885MAPT 1006/4885APP 2010/4885
US-20260001999-A1 HYDROPHILIC OIL REPELLENT POLYMER CCR1, H1-3, CCR3 CYP3A4 3394/4885MAPT 2871/4885APP 2676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.